Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 12/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.38 |
| ▸ | RPS6KA5 | O75582 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12604004 | 0.81 | RPS6KA5 (0.38) | RPS6KA5KDM4EMAPTALDH1A1 | |
| SCHEMBL22771494 | 0.77 | GRIN1 (0.37) | GRIN1GRIN2BRPS6KA5ALDH1A1 | |
| SCHEMBL28682811 | 0.76 | GRIN1 (0.34) | GRIN1GRIN2BRPS6KA5 | |
| SCHEMBL22771512 | 0.75 | RPS6KA5 (0.38) | GRIN1GRIN2BRPS6KA5KDM4E | |
| SCHEMBL27891755 | 0.75 | RPS6KA5 (0.41) | GRIN1GRIN2BRPS6KA5KDM4EMAPT | |
| SCHEMBL22771510 | 0.74 | GRIN1 (0.35) | GRIN1GRIN2B | |
| SCHEMBL25282474 | 0.74 | GRIN1 (0.41) | GRIN1GRIN2BRPS6KA5 | |
| SCHEMBL30304727 | 0.73 | GRIN1 (0.35) | GRIN1GRIN2BRPS6KA5 | |
| SCHEMBL22771500 | 0.73 | KMT2A (0.35) | GRIN1GRIN2BRPS6KA5KDM4E | |
| SCHEMBL9633839 | 0.71 | RPS6KA5 (0.41) | RPS6KA5KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143026-A | Synthesis method of heteroaryl trifluoromethyl compound | 上海毕得医药科技股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |